Skip Navigation


Annals of Oncology Advance Access originally published online on July 27, 2006
Annals of Oncology 2007 18(3):421-430; doi:10.1093/annonc/mdl175
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/3/421    most recent
mdl175v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cruz, J.
Right arrow Articles by Pandiella, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cruz, J.
Right arrow Articles by Pandiella, A
Related Collections
Right arrow 2007 - Review Articles
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

reviews

Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer

JJ Cruz, A Ocaña, E Del Barco and A Pandiella*

Servicio de Oncología, Hospital Universitario de Salamanca, Centro de Investigación del Cáncer; Instituto de Biología Molecular y Celular del Cáncer, CSIC-Universidad de Salamanca, Spain

* Correspondence to: Dr A. Pandiella, Instituto de Biología Molecular y Celular del Cáncer, Campus Miguel de Unamuno, 37007-Salamanca, Spain. Tel: +34-923-294815; E-mail: atanasio{at}usal.es

Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer in the world. At present several therapeutic approaches, including surgical removal, chemotherapy and radiotherapy, are used. Yet a significant number of patients relapse, often with metastases. In an attempt to improve treatment of SCCHN new targeted therapies are emerging. Among them special interest has been devoted to agents that act on the epidermal growth factor receptor (EGFR) and other receptor tyrosine kinases, or the signal transduction routes used by these receptors to induce tumour cell proliferation. Such treatments include monoclonal antibodies and small molecule inhibitors of either the intracellular tyrosine kinase activity of these receptors or relevant signalling intermediates. Here we review the biological bases of these new targeted treatments, with special emphasis on the clinical results that point to an implementation of these drugs into the therapeutic armamentarium against SCCHN.

Key words: head and neck cancer, receptor tyrosine kinases, targeted therapies

Received for publication April 12, 2006. Accepted for publication June 22, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. C. Montero, R. Rodriguez-Barrueco, A. Ocana, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella
Neuregulins and Cancer
Clin. Cancer Res., June 1, 2008; 14(11): 3237 - 3241.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ocana and A. Pandiella
Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options
Clin. Cancer Res., February 15, 2008; 14(4): 961 - 970.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. de Alava, A. Ocana, M. Abad, J. C. Montero, A. Esparis-Ogando, C. A. Rodriguez, A. P. Otero, T. Hernandez, J. J. Cruz, and A. Pandiella
Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2656 - 2663.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Karamouzis, P. Konstantinopoulos, and A. Papavassiliou
Intriguing issues of EGFR targeting in head and neck cancer
Ann. Onc., May 1, 2007; 18(5): 962 - 962.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.